Corcept Therapeutics Incorporated (NASDAQ: CORT)

Sector: Medical

Current Price : $1.88

52 Week Low
$1.2952 Week High
$4.49

Press Releases
Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call
New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012
Corcept Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results
Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success in 2012
Corcept Therapeutics Announces Fourth Quarter and Full Year Revenue and Corporate Update
Free Research Reports on CORT, CUR, EXM and SVU Issued by the Bedford Report
Free Research Reports on AVGO, CMTL, CORT and LNG Issued by the Bedford Report
The Reason It Trades, What's Moving PPHM, CORT, CTIC and ACTC
Perfect Trade Setups, How to Play PPHM, CORT, CTIC and ACTC
The Real Story Behind UEPS, CORT, ACLS and ASYS
Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012
Free Research Reports on CENX, CORT, DVR and IQNT Issued by the Bedford Report
Corcept Therapeutics Announces Third Quarter Results and Corporate Update
Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility
Corcept Therapeutics Announces Second Quarter Results and Corporate Update
Corcept Therapeutics Announces Underwritten Public Offering of Common Stock
Corcept Therapeutics Commences Public Offering of Common Stock
Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update
Corcept Therapeutics Announces National Product Launch of Korlym(TM) for Patients With Endogenous Cushing's Syndrome
UPDATE: Data Published in Premier Endocrinology Journal Shows Korlym(TM) Provides Significant Clinical Improvement in Patients With Endogenous Cushing's Syndrome
Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants
Korlym(TM) (mifepristone), the First Approved Medication for Patients With Endogenous Cushing's Syndrome, to Be Available by April 11
Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update
Corcept Therapeutics Incorporated Announces FDA Approval of Korlym(TM) (Mifepristone): First and Only Approved Medication for Cushing's Syndrome Patients
FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym(TM) for Cushing's Syndrome
Corcept Therapeutics Announces Third Quarter Results and Corporate and Development Update
No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome
Gary C. Robb Joins Corcept as Chief Financial Officer
Corcept Therapeutics Announces Second Quarter Results and Corporate and Development Update
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
Corcept Therapeutics Announces Detailed Findings From Phase 3 Study Which Show CORLUX Significantly Improves Clinical and Metabolic Manifestations of Cushing's Syndrome
Corcept Therapeutics Announces Conference Call to Discuss Detailed Findings From Corlux Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting
Corcept Therapeutics to Present Detailed Findings From CORLUX Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting, June 4-7
Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update
Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome
Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11, 2011
Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update
Corcept Therapeutics Announces Closing of $44.9 Million Underwritten Public Offering of Common Stock
Corcept Therapeutics Announces Pricing of $39.0 Million Underwritten Public Offering of Common Stock
Corcept Therapeutics Announces Proposed Public Offering of Common Stock
Corcept Therapeutics Announces Key Secondary Endpoint Was Met in Phase 3 Study of Corlux for Cushing's Syndrome

iStock Rating

Corcept Therapeutics Incorporated (NASDAQ: CORT)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios